Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients

Bone Marrow Transplant. 2022 Jul;57(7):1183-1186. doi: 10.1038/s41409-022-01675-w. Epub 2022 Apr 21.

Authors

Eleni Gavriilaki^#¹, Anastasia Papadopoulou^#¹, Tasoula Touloumenidou¹, Fani Stavridou¹, Evaggelia-Evdoxia Koravou¹, Maria Giannaki¹, Apostolia Papalexandri¹, Georgios Karavalakis¹, Ioannis Batsis¹, Andreas Kourelis², Fani Chatzopoulou², Dimitrios Chatzidimitriou², Damianos Sotiropoulos¹, Evangelia Yannaki³, Ioanna Sakellari¹, Achilles Anagnostopoulos¹

Affiliations

¹ Hematology Department - Hematopoietic Cell Transplant (HCT) Unit - Gene and Cell Therapy Center, George Papanikolaou Hospital, Thessaloniki, Greece.
² Microbiology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
³ Hematology Department - Hematopoietic Cell Transplant (HCT) Unit - Gene and Cell Therapy Center, George Papanikolaou Hospital, Thessaloniki, Greece. eyannaki@uw.edu.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
COVID-19* / prevention & control
Hematopoietic Stem Cell Transplantation*
Humans
SARS-CoV-2
T-Lymphocytes
Transplant Recipients
Vaccination

Substances

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines